907.25
0.90%
ICICI Securities Limited
Overall 15-20% revenue growth guidance for FY21 continued, hope to achieve same in FY22; EBITDA margins sustainable above 40% o Pharma CRAMS to also grow 15-20% YoY; specialty chemical...
Cohance Lifesciences Ltd. has lost -25.31% in the last 6 Months
More from Cohance Lifesciences Ltd.
Recommended